enzalutamide (xtandi) Report issue

Small molecule Approved FDA Fast Track FDA Priority Review FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Enzalutamide (brand name Xtandi) is an orally bioavailable, organic, non-steroidal small molecule targeting the androgen receptor (AR) with potential antineoplastic activity. It was developed at UCLA and marketed by the pharmaceutical company Medivation for the treatment of metastatic castration-resistant prostate cancer. Through a mechanism that is reported to be different from other approved AR antagonists, enzalutamide inhibits the activity of prostate cancer cell ARs, which may result in a reduction in prostate cancer cell proliferation and, correspondingly, a reduction in the serum prostate specific antigen (PSA) level. AR over-expression in prostate cancer represents a key mechanism associated with prostate cancer hormone resistance.   NCATS

Chemistry

  • SMILES: CNC(=O)C1=C(F)C=C(C=C1)N2C(=S)N(C(=O)C2(C)C)C3=CC(=C(C=C3)C#N)C(F)(F)F
  • InChIKey: WXCXUHSOUPDCQV-UHFFFAOYSA-N
  • Mol. Mass: 464.436
  • ALogP: 3.99
  • ChEMBL Molecule:
    enzalutamide  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Oral
  • Pro Drug: No

Drug Pricing (per unit)

Australia

$23.7420

United States

$62.5395
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

enzalutamide | ezalutamide | mdv3100 | mdv 3100 | mdv-3100 | xtandi

Organizations (191)

Research & Development (188)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (5)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (55)

Approved Indications (2)


 

Prostatic Neoplasms

Prostatic Neoplasms, Castration-Resistant (approved 2012)

Experimental Indications - Clinical Trial Phases 1-4 (55)


 

Androgens (Phase 2)

Anemia (Phase 1)

Biomarkers (Phase 1)

Breast Neoplasms (Phase 3)

Carcinoma, Hepatocellular (Phase 2)

Carcinoma, Renal Cell (Phase 1)

Carcinoma, Transitional Cell (Phase 1)

Castration (Phase 1/Phase 2)

Cerebrovascular Circulation (Phase 1)

Colorectal Neoplasms (Phase 1)

Coronavirus Infections (Phase 2)

COVID-19 (Phase 2)

DNA (Phase 2)

Drug Interactions (Phase 1)

Drugs, Investigational (Phase 1)

Endometrial Neoplasms (Phase 2)

Fallopian Tubes (Phase 2)

Fasting (Phase 1)

Hamartoma (Phase 2)

Healthy Volunteers (Phase 1)

Hodgkin Disease (Phase 1)

Kidney Diseases (Phase 1)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 1)

Leukemia, Myelogenous, Chronic, BCR-ABL Positive (Phase 1)

Leukemia, Myeloid, Acute (Phase 1)

Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative (Phase 1)

Leukemia, Myeloid, Chronic-Phase (Phase 1)

Leukemia, Myelomonocytic, Chronic (Phase 1)

Liver Diseases (Phase 1)

Liver Neoplasms (Phase 1)

Lymphoma (Phase 1)

Lymphoma, Non-Hodgkin (Phase 1)

Lymphoma, Primary Cutaneous Anaplastic Large Cell (Phase 1)

Melanoma (Phase 1)

Mesothelioma (Phase 1)

Multiple Myeloma (Phase 1)

Myelodysplastic Syndromes (Phase 1)

Myeloproliferative Disorders (Phase 1)

Neoplasm Metastasis (Phase 2/Phase 3)

Neoplasms ()

Neoplasms, Squamous Cell (Phase 1)

Ovarian Neoplasms (Phase 2)

Pancreatic Neoplasms (Phase 1)

Pelvis (Phase 2)

Pharmacokinetics (Phase 1)

Precursor B-Cell Lymphoblastic Leukemia-Lymphoma (Phase 1)

Primary Myelofibrosis (Phase 1)

Prostatic Neoplasms ()

Prostatic Neoplasms, Castration-Resistant (Phase 4)

Squamous Cell Carcinoma of Head and Neck (Phase 2)

Triple Negative Breast Neoplasms (Phase 2)

Ureteral Neoplasms (Phase 1)

Urethral Neoplasms (Phase 1)

Urinary Bladder Neoplasms (Phase 2)

Uterine Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 240
  • # of Trial Organizations: 188

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue